Showing 2 of 2 recruiting trials for “rare-hypolipidemia”
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
RecruitingNCT06676046 ↗
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
👨⚕️ Marcelo J Amar, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jan 2025View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →